A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis

NCT06451159 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Progressive Multiple Sclerosis

Interventions

BIOLOGICAL: KYV-101 (Biological) - 0.33 ×10^8 cells
BIOLOGICAL: KYV-101 (Biological) - 1 ×10^8 cells
DRUG: Chemotherapy: cyclophosphamide (CYC)
DRUG: Chemotherapy: fludarabine (FLU)

Sponsor

Bruce Cree

Collaborators

[object Object]